ARTICLE SUMMARY:
Big pharma Eli Lilly, a leader in the diabetes drug market, is working with medtech to create a “connected diabetes ecosystem,” all part of the company’s plan to shift its focus from molecules to outcomes. In this Q&A we learn more from Senior Director Matt Clemente, who heads up the project for Lilly.
Competitors in the diabetes arena are working to meet consumer demand for more digitally integrated and interconnected diabetes management solutions, and collaborations among the various participants represent the new norm in this industry.
